[Therapeutic trial of tiapride in ENT].
Tiapride was studied in 60 patients with ENT affections. The dosage was 1 to 2 ampoules IM a day for 7 to 10 days, followed by a half a tablet 3 to 4 times a day for 2 weeks to 2 months. Results were excellent or good for 16 out of 20 cases of essential headache, 6 out of 6 cases of Barré Liéou's syndrome, 7 out 8 cases of sinus pain, 6 out of 8 cases of Méniè's disease, and 6 out of 6 cases of facial paralysis "a frigore". In 7 cases of post-concussion syndrome, excellent results were observed in all the patients, on headache. Vertigo was reduced in intensity. The effects was moderate or nil on tinnitus and deafness due to Ménières syndrome, as well as in 2 casls of facial neuralgia. Tolorance was excellent as, in these 60 patients, only 2 cases of dry mouth and 1 case of vomiting in a diabetic were reported.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001549:Benzamides / Q000627:therapeutic use*; D002648:Child; D004361:Drug Tolerance; D005158:Facial Paralysis / Q000188:drug therapy; D005260:Female; D006261:Headache / Q000188:drug therapy; D006801:Humans; D008297:Male; D008575:Meniere Disease / Q000188:drug therapy; D008875:Middle Aged; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy*; D013128:Spinal Osteophytosis / Q000188:drug therapy
D001549:Benzamides
Essai thérapeutizue du tiapride en ORL.